InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | 2026-04-06 | GILL JOHN | Director | Purchase | 9,200 | $3.41 | $31K | 21.7K | View ↗ | |
| 2026-04-01 | 2026-04-01 | WEAVER GREGORY L | Chief Financial Officer | Purchase | 10.0K | $3.15 | $31K | 38.1K | View ↗ | |
| 2026-04-01 | 2026-04-01 | Durso Jerome Benedict | Director & President and CEO | Purchase | 15.0K | $3.14 | $47K | 47.5K | View ↗ | |
| 2026-03-06 | 2026-03-09 | WEAVER GREGORY L | Chief Financial Officer | Purchase | 5,000 | $3.54 | $18K | 28.1K | View ↗ | |
| 2026-03-06 | 2026-03-09 | Durso Jerome Benedict | Director & President and CEO | Purchase | 20.0K | $3.54 | $71K | 32.5K | View ↗ |
No annual data found.
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
Altimmune outlines PERFORMA Phase III MASH start in 2H 2026 and cash runway to 2029 52-week readout
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Altimmune Inc (ALT) Q1 2026 Earnings Call Highlights: Strong Cash Position and Strategic ...